Article
The Frequency of CYP2C19 Loss-of-Function Variants in Patients with Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack in the Dutch Population.
Cerebrovascular diseases (Basel, Switzerland) - 1 Jan 2023
van den Heuvel Lotte, Vermeer Henricus J, Kerkhoff Henk, Roozenbeek Bob, Zock Elles
Abstract excerpt
INTRODUCTION: The CYP2C19 enzyme converts clopidogrel into an active metabolite. Carriers of CYP2C19 loss-of-function (LOF) variants with a history of ischemic stroke or transient ischemic attack (TIA) using clopidogrel may have a higher risk of recurrent stroke. To study the implications of genetic CYP2C19 heterogeneity in treatment of cerebral ischemia, knowledge about the prevalence of CYP2C19 LOF variants...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
